Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study

IL‐23‐inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant. to indirectly compare the effectiveness, safety and tolerability of guselkumab and ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruggiero, Angelo, Fabbrocini, Gabriella, Cinelli, Eleonora, Megna, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285826/
https://www.ncbi.nlm.nih.gov/pubmed/34800070
http://dx.doi.org/10.1111/dth.15214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285826/
https://www.ncbi.nlm.nih.gov/pubmed/34800070
http://dx.doi.org/10.1111/dth.15214

Ejemplares similares